Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Peripheral Biomarkers & Treatment Response on Panic Symptoms in MDD

Higher pretreatment leptin was associated with better response to treatment regarding panic symptoms in patients with major depressive disorder (MDD), while higher IL-6 was associated with worse response regarding symptoms in those with panic disorder (PD), a new study found. 41 patients with MDD, 52 patients with PD, and 59 healthy controls were followed for 12 weeks. Researchers measured peripheral biomarkers along with the Panic Disorder Severity Scale (PDSS) at each visit: pretreatment 2, 4, 8, and 12 weeks on a regular schedule. They found:

  • Patients with MDD and PD showed significantly higher levels of pretreatment IL-6 compared to controls, but no differences were seen in plasma and serum BDNF, leptin, adiponectin, and CRP.
  • Pretreatment leptin demonstrated a significant clinical correlation with reduction of panic symptoms in patients with MDD at visit.
  • Pretreatment IL-6 showed a negative correlation with panic symptom reduction in patients with PD.

Citation:

Kim K, et al. Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: a 12-week follow-up study. [Published online ahead of print October 19, 2019]. Comprehensive Psychiatry. doi: 10.1016/j.comppysch.2019.152140.